Abstract
Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and thirdgeneration calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable “therapeutic cross effects” due to pleiotropic mechanisms can be defined as pleiosynergy.
Keywords: Statin, amlodipine, vascular effect, pleiotropic, synergy
Current Vascular Pharmacology
Title: Vascular Pleiosynergy - Does It Really Work?
Volume: 5 Issue: 4
Author(s): Albert Csaszar
Affiliation:
Keywords: Statin, amlodipine, vascular effect, pleiotropic, synergy
Abstract: Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and thirdgeneration calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable “therapeutic cross effects” due to pleiotropic mechanisms can be defined as pleiosynergy.
Export Options
About this article
Cite this article as:
Csaszar Albert, Vascular Pleiosynergy - Does It Really Work?, Current Vascular Pharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157016107782023352
DOI https://dx.doi.org/10.2174/157016107782023352 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review
Current Medicinal Chemistry Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Current Cancer Drug Targets Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Effects of β-glucan and Folium mori Extract Combinations in STZ-induced Diabetic Rats: Effectiveness of Various BGFM Complex Compositions in Treating Diabetes
Current Nutrition & Food Science Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Beta Blockers and Chronic Obstructive Pulmonary Disease (COPD): Sum of Evidence
Current Hypertension Reviews Insulin Resistance in Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design The Use of Unsaturated Fatty Acids in Liposomal Form to Get Bread Enriched with ω-3 Fatty Acids
Current Nutrition & Food Science Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium
Current Signal Transduction Therapy Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
Current Stem Cell Research & Therapy Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Influence of Ultrasound Mediated Transdermal Delivery of Losartan Potassium
Drug Delivery Letters